ASND logo

ASCENDIS PHARMA A/S

ASNDNASDAQ
🏆 #566 by market capUS Equity
——
Quote unavailable
🔔
Track ASND
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$17.46B
Mid Cap
📈Revenue Growth (YoY)
113.3%
High Growth
📊Gross Margin
91.3%
High
💵FCF Margin
33.5%
Strong
⚖️P/S Ratio
13.2x
Elevated
Otter Score
68
Fair
No chart data available for ASND.

Trading Snapshot

Day Range
—
52-Week Range
—
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
66.4M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$692M
Last Q Revenue
$345M
P/E Ratio
18.6
P/S Ratio
13.2x
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+2.7%
ASND logo

ASCENDIS PHARMA A/S

ASND
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$692M▲ +90.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
85.1%▼ −3.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$131M▼ −53.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$44M▼ −114.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
61.4M▲ +2.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$256M▲ +$41M YoY
StockOtter · stockotter.space

About ASCENDIS PHARMA A/S

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100
Analyst data unavailable.

Latest News & Updates

News unavailable.